HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?

AbstractBACKGROUND:
Cutaneous lupus erythematosus (CLE) can be a severe disease, characterized by extensive, disfiguring lesions and a relapsing course. Thalidomide is known as an effective treatment for CLE, however, its use is restricted by its potential side-effects. Nevertheless, it remains a valuable option to consider. Therefore, it is important to report new clinical experiences.
METHODS:
The data of 30 patients with refractory CLE, who were treated with thalidomide, were retrospectively analyzed. The response rate was categorized as complete, partial or no response. The relapse rate and the occurrence of side-effects were registered.
RESULTS:
Six patients prematurely discontinued treatment because of side-effects. The response rate was 100% in the remaining 24 patients, including 20 patients (83%) with complete response and 4 (27%) with partial response. Clinical relapse was frequent (73%) and occurred between 3 and 24 weeks after withdrawal of thalidomide. Nine patients (30%) developed peripheral neuropathy. In the majority, there was no complete resolution of the neuropathy-associated symptoms after stopping thalidomide. One patient developed a thrombosis in an artery stent.
CONCLUSION:
Because of high risk of polyneuropathy, low-dose thalidomide should be used and long-term therapy should be avoided. Therefore, it should be recommended to combine thalidomide with other treatments for CLE.
AuthorsIsabelle Baret, Petra De Haes
JournalThe Journal of dermatological treatment (J Dermatolog Treat) Vol. 26 Issue 2 Pg. 173-7 (Apr 2015) ISSN: 1471-1753 [Electronic] England
PMID24731053 (Publication Type: Journal Article)
Chemical References
  • Thalidomide
Topics
  • Adult
  • Aged
  • Female
  • Humans
  • Lupus Erythematosus, Cutaneous (drug therapy)
  • Male
  • Middle Aged
  • Recurrence
  • Retrospective Studies
  • Thalidomide (adverse effects, therapeutic use)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: